Sutimlimab vs B-Cell-Targeted Therapy in Cold Agglutinin Disease: Which Is the Optimal Approach?

Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by monoclonal IgM autoantibodies that bind to red blood cells and trigger hemolysis through activation of the classical complement pathway. Cold agglutinins are produced by a clonal population of lymphocytes recognized by the WHO as a low grade lymphoproliferative disorder. Traditional therapy relied on B-cell-targeted immunosuppression with rituximab which mainly yielded partial responses in about half of the patients. T